The Winged-Helix Protein Brain Factor 1 Interacts with Groucho and Hes Proteins To Repress Transcription

Por Yao, Jing, Lai, Eseng, Stifani, Stefano
Publicado em 2001

Foxg1 Is Required for Morphogenesis and Histogenesis of the Mammalian Inner Ear

Por Pauley, Sarah, Lai, Eseng, Fritzsch, Bernd
Publicado em 2006

FAST-2 Is a Mammalian Winged-Helix Protein Which Mediates Transforming Growth Factor β Signals

Por Liu, Bo, Dou, Chang-Lin, Prabhu, Leena, Lai, Eseng
Publicado em 1999

BF-1 Interferes with Transforming Growth Factor β Signaling by Associating with Smad Partners

Por Dou, Changlin, Lee, Jun, Liu, Bo, Liu, Fang, Massague, Joan, Xuan, Shouhong, Lai, Eseng
Publicado em 2000

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadeq...

Por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Sato, Asako, Okuyama, Kotoba, O’Neill, Edward A., Engel, Samuel S., Lai, Eseng
Publicado no Diabetes Ther (2017)

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2...

Por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado no Diabetes Obes Metab (2017)

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Por Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Publicado no Cardiovasc Diabetol (2017)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibito...

Por Goldenberg, Ronald, Gantz, Ira, Andryuk, Paula J., O'Neill, Edward A., Kaufman, Keith D., Lai, Eseng, Wang, Yin Na, Suryawanshi, Shailaja, Engel, Samuel S.
Publicado no Diabetes Obes Metab (2017)

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequ...

Por Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O’Neill, Edward A., Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado no BMC Endocr Disord (2017)

Antagonism of the prostaglandin D(2) receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

Por Cheng, Kang, Wu, Tsuei-Ju, Wu, Kenneth K., Sturino, Claudio, Metters, Kathleen, Gottesdiener, Keith, Wright, Samuel D., Wang, Zhaoyin, O’Neill, Gary, Lai, Eseng, Waters, M. Gerard
Publicado em 2006

Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Patients

Por Reitman, Marc L., Dishy, Victor, Moreau, Allison, Denney, William S., Liu, Chengcheng, Kraft, Walter K., Mejia, Alex V., Matson, Mark A., Stoch, S. Aubrey, Wagner, John A., Lai, Eseng
Publicado no J Clin Pharmacol (2011)

Pharmacokinetic–pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects

Por Wright, D Hamish, Stone, Julie A, Crumley, Tami M, Wenning, Larissa, Zheng, Wei, Yan, Kerri, Yang, Amy Yifan, Sun, Li, Cilissen, Caroline, Ramael, Steven, Hermanowski-Vosatka, Anne, Langdon, Ronald B, Gottesdiener, Keith M, Wagner, John A, Lai, Eseng
Publicado em 2013